Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

NCT06112808 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT06112808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06112808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Lead sponsor
Biocad
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 29, 2023
Completion date
January 31, 2027
Enrollment
300 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma